All Stories

  1. Clinical practice guideline recommendation summaries for pediatric oncology health care professionals: A qualitative study
  2. Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults
  3. Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis
  4. Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group
  5. Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry
  6. Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma
  7. Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review
  8. Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study
  9. Validation of the Proxy Version of Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments
  10. Response to ‘Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives’
  11. Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial
  12. Aprepitant and fosaprepitant drug interactions: a systematic review
  13. Nausea and vomiting in children and adolescents receiving intrathecal methotrexate: A prospective, observational study
  14. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update
  15. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children
  16. 2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy
  17. The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis
  18. Guideline on children with challenging chemotherapy-induced nausea and vomiting
  19. Chemotherapy-induced vomiting in children: some progress, more questions
  20. The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis
  21. Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology Group
  22. Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group
  23. Reply to “Pharmacokinetic and Analytical Issues in Busulfan Area Under the Curve Estimation and Simulation”
  24. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis
  25. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning
  26. A review of symptom screening tools in pediatric cancer patients
  27. Methodological issues identified during cognitive interviews in the development of a pediatric cancer symptom screening tool
  28. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review
  29. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
  30. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective, multi-center review
  31. The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis
  32. Refinement of the Symptom Screening in Pediatrics Tool (SSPedi)
  33. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients
  34. Comparative effectiveness research in antineoplastic-induced nausea and vomiting control in children
  35. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients
  36. Erratum to: Initial development of the Symptom Screening in Pediatrics Tool (SSPedi)
  37. Initial development of the Symptom Screening in Pediatrics Tool (SSPedi)
  38. Methylnaltrexone for Opioid-Induced Constipation in Pediatric Oncology Patients
  39. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients
  40. Development and Testing of a Multidimensional iPhone Pain Assessment Application for Adolescents with Cancer
  41. Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation
  42. Children's Oncology Group's 2013 blueprint for research: Cancer control and supportive care
  43. Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children
  44. Fluoroquinolones in Children With Fever and Neutropenia
  45. A Meta-analysis of Antipseudomonal Penicillins and Cephalosporins in Pediatric Patients With Fever and Neutropenia
  46. Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children—a systematic review of prospective trials
  47. A systematic review of symptom assessment scales in children with cancer
  48. A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia
  49. A Reliable and Safe Method of Collecting Blood Samples from Implantable Central Venous Catheters for Determination of Plasma Gentamicin Concentrations
  50. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients
  51. Cyclosporine Dose Intensity and Risk of Acute Graft-versus-Host Disease: Trough versus Area under the Curve
  52. Practice Spotlight: Supportive Care Research in Pediatric Oncology
  53. Dismal response to high-dose methylprednisolone after failure to respond to standard dose in patients with acute GVHD
  54. Optimizing Emetic Control in Children Receiving Antineoplastic Therapy
  55. Once-Daily Gentamicin Dosing in Children with Febrile Neutropenia Resulting from Antineoplastic Therapy
  56. Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic Leukemia
  57. Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line
  58. Symptom assessment in children receiving cancer therapy: the parents’ perspective
  59. Daclizumab therapy for children with corticosteroid-resistant acute graft-vs.-host disease
  60. Cyclosporine-Induced Pain Syndrome in a Child Undergoing Hematopoietic Stem Cell Transplant
  61. Stability of an extemporaneous oral liquid aprepitant formulation
  62. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome
  63. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients
  64. Determination of Area Under the Whole Blood Concentration versus Time Curve after First Intravenous Cyclosporine Dose in Children Undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies
  65. IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies
  66. Sevelamer hydrochloride: A novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children
  67. Documentation of Pediatric Drug Safety in Manufacturers??? Product Monographs
  68. Achievement of Target Cyclosporine Concentrations as a Predictor of Severe Acute Graft Versus Host Disease in Children Undergoing Hematopoietic Stem Cell Transplantation and Receiving Cyclosporine and Methotrexate Prophylaxis
  69. Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation
  70. EFFICACY AND SAFETY OF CASPOFUNGIN FOR THE EMPIRIC MANAGEMENT OF FEVER IN NEUTROPENIC CHILDREN
  71. Pharmacokinetic Disposition and Clinical Outcomes in Infants and Children Receiving Intravenous Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation
  72. Defibrotide for the treatment of hepatic veno-occlusive disease in children
  73. Extent of Agreement in Gentamicin Concentration Between Serum That Is Drawn Peripherally and From Central Venous Catheters
  74. Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents
  75. Medication Safety: Occurrence and Impact of Unanticipated Variation in Intravenous Methotrexate Dosing
  76. Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation
  77. Disposition of Two Oral Formulations of Cyclosporine in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants
  78. Pediatric Pharmacotherapeutic Education: Current Status and Recommendations to Fill the Growing Need
  79. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design
  80. Appropriate busulfan dosing
  81. Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once-Daily versus Thrice-Daily Administration
  82. Predictors of Viridans Streptococcal Shock Syndrome in Bacteremic Children With Cancer and Stem-Cell Transplant Recipients
  83. Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study
  84. Retrospective appraisal of busulfan dose adjustment in children
  85. Pharmacologic Management of Painful Oncology Procedures in Pediatrics
  86. Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children
  87. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation
  88. Therapeutic Drug Monitoring of Lamotrigine
  89. Therapeutic Drug Monitoring of Lamotrigine
  90. Delayed nausea and vomiting in children receiving antineoplastics
  91. VINCRISTINE TOXICITY
  92. Hyperpigmentation due to topical application of silver sulfadiazine cream